Toronto-based Xagenic nabs $20 mln in Series B funds
Xagenic said Monday that it has closed $20 million in Series B financing. New investor Domain Associates led the round with participation from return backers CTI Life Sciences Fund and the Ontario Emerging Technologies Fund. Also, the company named Dr. Jesse Treu, a partner at Domain Associates, to its board of directors. Based in Toronto, Xagenic is a molecular diagnostics company.
2 December 2013•4 mins read
